drugset / Trial / NCT03301883
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
NaSingle-groupOpen-labelTreatment
Summary
This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) and steroid therapy.
Timeline
- Start
- 2018-04-26
- Primary completion
- 2021-09-04
- Completion
- 2022-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Background | MTX | Unknown | 20 mg/m2 | — |